Status:
UNKNOWN
Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
Treatment with statins has a class I indication after percutaneous coronary intervention (PCI), but is often discontinued by patients due to side effects. Pharmacologic alternatives shown to be usefu...
Detailed Description
Background Treatment with statins has a class I indication after percutaneous coronary intervention (PCI), but is often discontinued by patients due to side effects. Pharmacologic alternatives shown...
Eligibility Criteria
Inclusion
- Angiographically-proven coronary artery disease
- Recent (\<12 months) percutaneous coronary intervention
- Class I indication to receive statin treatment
- Previous (\<12 months) withdrawn of a statin due to side effects
- Unwilling to receive treatment with an alternative statin
- Able to understand and willing to sign the informed consent form
Exclusion
- • Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before CT
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01807078
Start Date
January 1 2014
End Date
December 1 2017
Last Update
March 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sapienza University
Rome, Lazio, Italy, 00161